Please assess the completion status of the following clinical trial:

Trial Title: Effect of Second-look Endoscopy on Peptic Ulcer Rebleeding in Patients With Early Resumption of Antiplatelet Agents

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Antiplatelet for both primary and secondary prophylaxis~* Peptic ulcers of Forrest class Ia (spurting of blood), Ib (oozing of blood), IIa (visible vessel) \& IIb (adherent clot)~Exclusion Criteria:~* Peptic ulcers of class IIc (pigmented ulcer base) \& III (clean ulcer base)~* Unsuccessful endoscopic hemostasis~* Ulcer perforation~* Gastric outlet obstruction precluding passage of scope to D2~* Malignant ulcers~* Proton pump inhibitor (PPI) allergy~* Concomitant anticoagulants~* Pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Second-look OGD group (Type: EXPERIMENTAL): Second-look OGD within 16 to 24 hours after primary OGD, in addition to standard care (esomeprazole infusion for three days, followed by oral esomeprazole.~OGD will be offered if signs of rebleeding present)
- Standard care group (Type: ACTIVE_COMPARATOR): Esomeprazole infusion for three days, followed by oral esomeprazole. OGD will be offered if signs of rebleeding present

Based on this trial design, predict the completion outcome and termination type (if applicable).